Advertisement
U.S. markets open in 5 hours 51 minutes
  • S&P Futures

    5,210.00
    -4.75 (-0.09%)
     
  • Dow Futures

    39,228.00
    +5.00 (+0.01%)
     
  • Nasdaq Futures

    18,188.50
    -43.00 (-0.24%)
     
  • Russell 2000 Futures

    2,048.00
    -1.80 (-0.09%)
     
  • Crude Oil

    82.70
    -0.02 (-0.02%)
     
  • Gold

    2,158.60
    -5.70 (-0.26%)
     
  • Silver

    25.15
    -0.11 (-0.46%)
     
  • EUR/USD

    1.0865
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.51
    +0.18 (+1.26%)
     
  • GBP/USD

    1.2705
    -0.0023 (-0.18%)
     
  • USD/JPY

    150.2040
    +1.1060 (+0.74%)
     
  • Bitcoin USD

    64,269.22
    -4,010.45 (-5.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

ENDRA Life Sciences to Present at H.C. Wainwright Virtual BioConnect 2021 Conference

ANN ARBOR, MI / ACCESSWIRE / January 8, 2021 / ENDRA Life Sciences Inc. (ENDRA) (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that Chairman and CEO Francois Michelon will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021. The presentation can be accessed here and on the Investor Relations section of the ENDRA website beginning on January 11, 2021 at 6:00 a.m. Eastern time and will be archived for 90 days.

About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the over 1 million ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over 1 billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Company Contact:
David Wells
Chief Financial Officer
(734) 997-0464
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:
Kim Sutton Golodetz
LHA Investor Relations
(212) 838-3777
kgolodetz@lhai.com

SOURCE: ENDRA Life Sciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/623551/ENDRA-Life-Sciences-to-Present-at-HC-Wainwright-Virtual-BioConnect-2021-Conference

Advertisement